Patent · US Active

Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes

US9970006B2 · kind B2 · utility

2Cited by

3References

15Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Brian Bettencourt · Groton, US
Kevin Fitzgerald · Brookline, US
Stuart Milstein · Cambridge, US
Martin Maier · Cambridge, US
Klaus Charisse · Acton, US
Kallanthottathil G. Rajeev · Wayland, US
Satyanarayana Kuchimanchi · Cambridge, US
Muthiah Manoharan · Carlsbad, US
Tuyen Nguyen · Randolph, US

Key dates

Filing date	Mar 21, 2016
Grant date	May 15, 2018
Priority date	—
Expiry date	Mar 21, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/3521
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.